Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ET-901 by EdiGene for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval
ET-901 is under clinical development by EdiGene and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma. According to...
ET-901 by EdiGene for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval
ET-901 is under clinical development by EdiGene and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid...
ET-901 by EdiGene for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval
ET-901 is under clinical development by EdiGene and currently in Phase II for Nodal Marginal Zone B-Cell Lymphoma. According to...
ET-901 by EdiGene for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
ET-901 is under clinical development by EdiGene and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData,...
ET-901 by EdiGene for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
ET-901 is under clinical development by EdiGene and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase...
ET-901 by EdiGene for Follicular Lymphoma: Likelihood of Approval
ET-901 is under clinical development by EdiGene and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...
ET-901 by EdiGene for Mantle Cell Lymphoma: Likelihood of Approval
ET-901 is under clinical development by EdiGene and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase...
ET-901 by EdiGene for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
ET-901 is under clinical development by EdiGene and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData,...